An independent nonprofit organization that evaluates clinical and cost effectiveness of new medicines found the price of GlaxoSmithKline’s new drug for severe asthma should be as much as 76 percent lower to justify its value, according to the group’s latest draft report. The Boston-based Institute for Clinical and Economic Review (ICER) said its analysis indicated that Glaxo’s Nucala should be priced at $7,800 to about $12,000 a year, far below the drug’s list price of $32,500 a year. It found that once-monthly injectable Nucala, which won U.S. approval last month, significantly reduces asthma attacks and symptoms and decreases the need for oral steroids.
More:
Independent group says new Glaxo asthma drug far too expensive